The KGH Research Institute is dedicated to building innovative partnerships, building innovative partnerships and pursuing research excellence through a collaborative approach that leverages the combined strengths of our Kingston hospital and Queen's University partners. This year, KGHRI is leading an initiative to establish a unified Kingston-wide research institute in which we can all work together to generate and translate new knowledge into effective therapies, treatments and best practices that benefit patients everywhere.
The Kingston-wide health research enterprise is among the "Top 10" health research institutes in Canada
In 2016-17 we will:
Establish a Kingston-wide health research enterprise agreement
How are we doing?
In our third quarter (Q3), October to December, we presented additional information requested by the Queen's Board of Trustees to the Queen’s University’s Board Capital Assets and Finance Committee regarding the creation of the new Integrated Kingston Health Research Institute (IRI) . The Capital Assets and Finance Committee have now endorsed the IRI proposal and we will move forward to full presentation to the Queen's Board of Trustees in March 2017. Subsequent to presumed approval by the Board of Trustees, early steps will involve creation of a CRA approved research institute as a non share capital trust with charitable status. It is anticipated that this will now occur in F2018 (summer and fall 2017). The University's approval is critical to our success in building a world class academic research enterprise that is well positioned to compete for scarce research dollars, while attracting leading researchers, students and trainees. The new IRI will be able to leverage economies of scale, combine resources and develop priorities that should lead to greater optimization of financial resources, stronger research outcomes and greater visibility for health research in Kingston.
We also worked with Queen’s and Hotel Dieu Hospital to revise the sections of our existing Affiliation Agreement that deal with research. This brings our agreement up-to-date with our current practices and positions us well for our accreditation within the Queen’s Faculty of Health Sciences. Once this revised agreement has been approved by all our hospital and university stakeholders, it will be used as a template for similar agreements with all three Kingston hospitals as we work towards the creation of our integrated research institute. It is anticipated that a new fully executed Affiliation Agreement for HDH and KGH will be finalized by the end of the next quarter. Working with PARTEQ Research and Development Innovations (PARTEQ) and HDH we also revised sections of our existing Management and License Agreement with PARTEQ related to innovation disclosures and commercialization of intellectual property. Once this revised agreement has been approved by all stakeholders, it will be used as a template for similar agreements with all three Kingston hospitals.
The William J. Henderson Centre for Patient-Oriented Research, once complete, will be a game-changer for research in the Kingston region and will also help to enhance research space for the new IRI. Construction has commenced on the approximately 10,000 square-foot facility which once complete will offer clinicians and basic sciences, nursing, and allied health researchers the ability to bring innovative diagnostic and therapeutic approaches to the point of care. While we initially anticipated that the new centre would be completed and occupied by April 2017, we have adjusted the pace of the construction in order to minimize the impact on patient care at the hospital and are now anticipating a September 2017 completion and occupation date. In another area of the hospital, Dr. Elaine Petrof's new RE-POOPULATE lab in our Gastrointestinal Diseases Research Unit (GIDRU) is now fully operational. Dr. Petrof, and a multi institutional team, was awarded earlier this year major funding from the U.S. National Institutes of Health. The new lab will enable Dr. Petrof to further develop RE POOPULATE, a synthetically derived alternative to fecal transplants used to treat recurrent C. difficile infection. Dr. Petrof is working with colleagues at the University of Guelph and Western University on the synthetic stool product. The group’s goal is to develop a more effective fecal transplant treatment for recurrent C. difficile.
ARE WE ON TRACK TO MEET THE TARGET BY YEAR END (March 31, 2017)?
Even though we have made significant progress this fiscal year, due to factors beyond our control we will not meet our target by year end. We now anticipate receiving approval by the Queen's Board of Trustees by year end. Therefore, the new IRI will not be incorporated and operational until later next fiscal year, putting us nine to 12 months beyond our original timeline. The William J. Henderson Centre for Patient‑Oriented Research, which was originally slated to be completed by Q4 this fiscal year, will not be open until Q3 of next fiscal.